Intas Pharmaceuticals' Troubles with FDA Continue

This report discusses the Warning Letter given to Intas Pharmaceuticals, which focuses on data integrity and the failure of management to fulfill specific responsibilities.

Redica Systems will add additional content to this report in the coming weeks.